Current topics in testosterone replacement of hypogonadal men

Nieschlag, Eberhard

doi:10.1016/j.beem.2014.09.008

Cited by 49 publications

(46 citation statements)

References 94 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Injectable T undecanoate at the dose of 1000 mg represents a significant improvement because injections may be spaced at 10‐ to 12‐week intervals, or even longer and T levels, although still fluctuating, are more stable compared with short‐acting formulations. In the hypogonadal male, this preparation has been associated with rare cases of pulmonary oil microembolism (1·5 per 10 000 injections) …”

Section: Most Commonly Used Formulations and Dosesmentioning

confidence: 99%

“…In the hypogonadal male, this preparation has been associated with rare cases of pulmonary oil microembolism (1Á5 per 10 000 injections). 24 The use of transdermal formulations is also possible, such as T gel (25-100 mg per day depending on blood levels) or patches (2Á5-7Á5 mg per day). Transdermal preparations enable the achievement and maintenance of stable concentrations of T which mimic the normal physiological male circadian rhythm of T. Possible disadvantages associated with this method of administration are skin irritation and the risk of T gel transfer to others.…”

Section: Testosterone Formulationsmentioning

confidence: 99%

See 1 more Smart Citation

Endocrine care of transpeople part I. A review of cross‐sex hormonal treatments, outcomes and adverse effects in transmen

Meriggiola

Gava

2015

Clinical Endocrinology

View full text Add to dashboard Cite

Summary Gender dysphoria (GD) is characterized by discomfort with the assigned or birth gender and the urge to live as a member of the desired sex. The goal of medical and surgical treatment is to improve the well‐being and quality of life of transpeople. The acquisition of phenotypic features of the desired gender requires the use of cross‐sex hormonal therapy (CHT). Adult transmen are treated with testosterone to induce virilization. In adolescents with severe and persistent GD, consideration can be given to arresting puberty at Tanner Stage II and if dysphoria persists, CHT is generally started after 16 years of age. Currently available short‐ and long‐term safety studies suggest that CHT is reasonably safe in transmen. Monitoring of transmen should be more frequent during the first year of cross‐sex hormone administration reducing to once or twice per year thereafter. Long‐term monitoring after sex reassignment surgery (SRS) includes annual check‐ups as are carried out for natal hypogonadal men. In elderly transmen, special attention should be paid to haematocrit in particular. Screening for breast and cervical cancer should be continued in transmen not undergoing SRS.

show abstract

Section: Most Commonly Used Formulations and Dosesmentioning

confidence: 99%

Section: Testosterone Formulationsmentioning

confidence: 99%

Endocrine care of transpeople part I. A review of cross‐sex hormonal treatments, outcomes and adverse effects in transmen

Meriggiola

Gava

2015

Clinical Endocrinology

View full text Add to dashboard Cite

show abstract

“…However, TU is expensive and, unlike for hypogonadal men in most countries, is not covered by insurance or by the national welfare when administered in transmen. In the hypogonadal men, TU has been associated with rare cases of pulmonary oil microembolism (1.5 per 10 000 injections) . TE, on the other hand, requires frequent injections resulting in peaks and troughs in T levels that may have consequences on mood and various health parameters, in particular on the rate of erythrocytosis which is higher in subjects receiving short‐acting intramuscular injections .…”

Section: Introductionmentioning

confidence: 99%

Testosterone undecanoate and testosterone enanthate injections are both effective and safe in transmen over 5 years of administration

Gava

Mancini

Cerpolini

et al. 2018

Clinical Endocrinology

View full text Add to dashboard Cite

show abstract

“…21 TRT can improve the age-related symptoms associated with muscle strength 22 and BMD, 10 and might improve overall physical performance. One of the possible explanations for the positive influence on the AMS score by DUT treatment might be due to reciprocal elevation of TT and estrogen by aromatase despite strong suppression of DHT, because testosterone directly binds the AR and has a more important role than DHT in target tissues where 5-alpha reductase is expressed less, though DHT has 2-10-fold higher affinity with AR than testosterone.…”

Section: Discussionmentioning

confidence: 99%

Influence of dutasteride treatment on serum hormone levels and aging male symptoms in patients with benign prostatic enlargement

et al. 2017

View full text Add to dashboard Cite

Objectives: To clarify the effects of dutasteride on serum hormone levels and aging male symptoms in patients with benign prostatic enlargement. Methods: The present prospective study was carried out in 110 symptomatic benign prostatic enlargement patients treated with daily administration of 0.5 mg dutasteride. We analyzed serum hormonal levels and aging related symptoms using a validated Aging Male Symptom questionnaire at baseline and after 3 months of dutasteride treatment. Results: The mean total testosterone, free testosterone and luteinizing hormone levels after dutasteride treatment were approximately 20% higher than those at baseline. The percentage increases in total and free testosterone levels were negatively correlated with these baseline levels. Baseline age, levels of total testosterone and free testosterone, and the changes in the rate of luteinizing hormone after dutasteride treatment tended to be correlated with an increase in the rate of total testosterone and free testosterone after dutasteride treatment. In a subgroup of 26 patients with moderate-to-severe aging male symptoms, poor morning erection and free testosterone levels <8.5 pg/mL, total aging male symptoms, and somatic symptoms scores significantly decreased after dutasteride treatment with an increase of total and free testosterone. Conclusions: The increase of endogenous free testosterone and total testosterone by dutasteride might bring additional benefits of improvement of aging male-related symptoms, especially in patients with lower free testosterone baseline levels and moderate-to-poor aging-related symptoms.

show abstract

Current topics in testosterone replacement of hypogonadal men

Cited by 49 publications

References 94 publications

Endocrine care of transpeople part I. A review of cross‐sex hormonal treatments, outcomes and adverse effects in transmen

Endocrine care of transpeople part I. A review of cross‐sex hormonal treatments, outcomes and adverse effects in transmen

Testosterone undecanoate and testosterone enanthate injections are both effective and safe in transmen over 5 years of administration

Influence of dutasteride treatment on serum hormone levels and aging male symptoms in patients with benign prostatic enlargement

Contact Info

Product

Resources

About